Danielle Brill Stock Analyst Profile - Truist Securities Research Coverage - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Danielle Brill

    Stock Analyst at Truist Securities

    (3.7)
    # 2400
    Out of 5,506 analysts
    99
    Total ratings
    Success rate
    Average return
    Main Sectors:
    Healthcare
    Top Industries:
    Biotechnology Drug Manufacturers - Specialty & Generic Drug Manufacturers - General

    30 Stocks

    Name Action PT Current % Upside Ratings Updated
    PVLA Palvella Therapeutic...
    Maintains: Strong Buy
    56 80
    		65.78 21.62% 2 Oct 2, 2025
    VRTX Vertex Pharmaceutica...
    Initiates Coverage On: Market Perform
    n/a
    		n/a n/a 3 Sep 3, 2025
    IRON Disc Medicine
    Initiates Coverage On: Buy
    86
    		67.78 26.88% 6 Jul 21, 2025
    ALNY Alnylam Pharmaceutic...
    Initiates Coverage On: Buy
    385
    		456.35 -15.63% 1 Jul 21, 2025
    HRMY Harmony Biosciences ...
    Initiates Coverage On: Buy
    48
    		27.28 75.95% 8 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    64
    		15.24 319.95% 2 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    163
    		137.03 18.95% 6 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    66
    		52.86 24.86% 1 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    30
    		23.23 29.14% 1 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    24
    		18.16 32.16% 1 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Upgrades: Strong Buy
    20 52
    		54.92 -5.32% 6 Dec 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Market Perform
    n/a
    		n/a n/a 1 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    79
    		55.43 42.52% 1 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    18
    		10.43 72.58% 1 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    36
    		16.9 113.02% 4 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    150
    		22.64 562.54% 3 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Market Perform
    n/a
    		n/a n/a 2 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Market Perform
    n/a
    		n/a n/a 2 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Strong Buy
    605
    		800 -24.38% 7 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Market Perform
    n/a
    		n/a n/a 5 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    50
    		39.61 26.23% 2 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    51
    		40.5 25.93% 2 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Maintains: Outperform
    180 100
    		7.97 1154.71% 5 Nov 14, 2023
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Underperform
    n/a
    		n/a n/a 9 Sep 18, 2023
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Market Perform
    n/a
    		n/a n/a 5 Jun 27, 2023
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Market Perform
    n/a
    		n/a n/a 3 Oct 4, 2021
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Neutral
    75 50
    		n/a n/a 5 Jan 20, 2021
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Market Perform
    n/a
    		n/a n/a 1 Aug 25, 2020
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Market Perform
    n/a
    		n/a n/a 1 Aug 25, 2020
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Hold
    n/a
    		n/a n/a 3 Sep 17, 2019